Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Structure Therapeutics, Inc. Sponsored ADR ( (GPCR) ) has shared an update.
On May 7, 2026, Structure Therapeutics amended and restated its at-the-market sales agreement with Leerink Partners and Cantor Fitzgerald, removing the cap on American Depositary Shares that can be issued and filing a prospectus supplement to lift its total ATM capacity to $400 million, after previously raising about $58.5 million, bolstering financial flexibility ahead of late-stage trials. That same day, the company reported first-quarter 2026 results, highlighting strong Phase 2 data for obesity drug aleniglipron with placebo-adjusted weight loss up to 16.3% at 44 weeks, positive end-of-Phase 2 FDA feedback supporting a Phase 3 launch in Q3 2026, advancing oral amylin candidates toward Phase 1 data, and a cash position of $1.5 billion expected to fund operations through 2028 as it invests heavily in R&D to strengthen its competitive position in the rapidly evolving obesity treatment market.
The most recent analyst rating on (GPCR) stock is a Buy with a $101.00 price target. To see the full list of analyst forecasts on Structure Therapeutics, Inc. Sponsored ADR stock, see the GPCR Stock Forecast page.
Spark’s Take on GPCR Stock
According to Spark, TipRanks’ AI Analyst, GPCR is a Neutral.
The score is driven primarily by solid balance-sheet strength and positive clinical/operational catalysts, offset by the highest-risk factor of continued pre-revenue status with expanding losses and steep cash burn. Technicals and valuation are neutral-to-slightly negative and do not meaningfully improve the risk/reward profile near term.
To see Spark’s full report on GPCR stock, click here.
More about Structure Therapeutics, Inc. Sponsored ADR
Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company focused on developing novel oral small molecule therapeutics for metabolic diseases, particularly obesity. Its pipeline centers on aleniglipron, an oral GLP-1 receptor agonist, and oral small molecule amylin receptor agonists such as ACCG-2671 and ACCG-3535, targeting more accessible, fixed-dose oral treatments for chronic weight management and related conditions.
Average Trading Volume: 940,657
Technical Sentiment Signal: Hold
Current Market Cap: $2.89B
Learn more about GPCR stock on TipRanks’ Stock Analysis page.